Trigen (Germany), a drug development company developing biologics for use in antithrombotic therapy, has appointed Dr Ayad Abdul-Ahad chief executive officer and Dr Norbert Bender chief medical officer. Dr Abdul-Ahad joins from Biogen Idec, where he served as vice-president and head of international medical affairs; he has also worked at Berlex Laboratories, AstraZeneca, SmithKline Beecham and Serono. Dr Bender has more than 10 years' experience as a medical doctor and has more than 15 years' experience in pharmaceutical companies, having previously worked at Hoescht, BASF Pharma Knoll, Cardion and The Vaccines Company.
Trigen makes two appointments
Trigen (Germany), a drug development company developing biologics for use in antithrombotic therapy, has appointed Dr Ayad Abdul-Ahad chief executive officer and Dr Norbert Bender chief medical officer. Dr Abdul-Ahad joins from [C#198601366:Biogen Idec], where he served as vice-president and head of international medical affairs; he has also worked at Berlex Laboratories, [C#198601342:AstraZeneca], SmithKline Beecham and Serono. Dr Bender has more than 10 years' experience as a medical doctor and has more than 15 years' experience in pharmaceutical companies, having previously worked at Hoescht, BASF Pharma Knoll, [C#199700461:Cardion] and The Vaccines Company.